losartan has been researched along with Coronary Artery Disease in 18 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-seven consecutive patients with coronary artery disease were randomly assigned to the following three treatment groups for 8 weeks: simvastatin 5 mg/day (n = 10); losartan 50 mg/day (n = 9); or control (usual treatment; n = 8)." | 9.12 | Different effects of simvastatin and losartan on cytokine levels in coronary artery disease. ( Kakizoe, H; Sadamatsu, K; Seto, T; Shimokawa, H; Tashiro, H; Yamamoto, K, 2006) |
| " In Study 2, 44 patients with acute myocardial infarction who randomly received an initial lower dose of either valsartan or losartan after stenting were evaluated." | 9.12 | Do valsartan and losartan have the same effects in the treatment of coronary artery disease? ( Imaizumi, S; Iwata, A; Kiya, Y; Kumagai, K; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Shirai, K; Zhang, B, 2007) |
| "With regard to the medications, Atorvastatin, Losartan and Captopril were administered more in patients (groups 1, 2 and 3) than the patients without hypertension and CAD." | 7.83 | Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension. ( Asadikaram, G; Ebrahimi, N; Kazemi Arababadi, M; Kiani, Z; Kohan, F; Masoumi, M; Nasiri, AA; Sepehri, Z; Sheikh Fathollahi, M, 2016) |
| "The aim is to explore the treatment effect of coronary artery disease (CAD) and hypertension on plasma levels of renalase activity and also the possible association of renalase rs10887800 gene polymorphism with CAD and hypertension." | 5.51 | Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism. ( Akbari, H; Asadikaram, G; Masoumi, M; Vakili, S, 2019) |
| "We think that losartan should be recommended to use for protection against atherosclerosis at the young aged individuals that have multiple risks for atherosclerosis, other than hypertension." | 5.13 | [The effect of losartan on the intima-media thickness of carotid artery]. ( Köseoğlu, K; Sönmez, HM; Turan, FC, 2008) |
| "Twenty-seven consecutive patients with coronary artery disease were randomly assigned to the following three treatment groups for 8 weeks: simvastatin 5 mg/day (n = 10); losartan 50 mg/day (n = 9); or control (usual treatment; n = 8)." | 5.12 | Different effects of simvastatin and losartan on cytokine levels in coronary artery disease. ( Kakizoe, H; Sadamatsu, K; Seto, T; Shimokawa, H; Tashiro, H; Yamamoto, K, 2006) |
| " In Study 2, 44 patients with acute myocardial infarction who randomly received an initial lower dose of either valsartan or losartan after stenting were evaluated." | 5.12 | Do valsartan and losartan have the same effects in the treatment of coronary artery disease? ( Imaizumi, S; Iwata, A; Kiya, Y; Kumagai, K; Matsuo, K; Miura, S; Nishikawa, H; Saku, K; Shimomura, H; Shirai, K; Zhang, B, 2007) |
| "Because no controlled clinical studies are available about the possible role of angiotensin II receptor blockers in preventing effort myocardial ischemia, we evaluated the effect of angiotensin II receptor blocker/losartan in preventing exercise-induced myocardial ischemia in patients with coronary artery disease." | 5.12 | Effect of losartan in treatment of exercise-induced myocardial ischemia. ( Abete, P; Cacciatore, F; Corbi, G; Ferrara, N; Furgi, G; Longobardi, G; Rengo, F; Vitale, DF, 2007) |
| "With regard to the medications, Atorvastatin, Losartan and Captopril were administered more in patients (groups 1, 2 and 3) than the patients without hypertension and CAD." | 3.83 | Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension. ( Asadikaram, G; Ebrahimi, N; Kazemi Arababadi, M; Kiani, Z; Kohan, F; Masoumi, M; Nasiri, AA; Sepehri, Z; Sheikh Fathollahi, M, 2016) |
| " Further research is necessary to determine which AT1RBs and which dosing regimens are optimal." | 2.41 | Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. ( Mancini, GB, 2002) |
| "The aim is to explore the treatment effect of coronary artery disease (CAD) and hypertension on plasma levels of renalase activity and also the possible association of renalase rs10887800 gene polymorphism with CAD and hypertension." | 1.51 | Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism. ( Akbari, H; Asadikaram, G; Masoumi, M; Vakili, S, 2019) |
| "Treatment with losartan decreased systolic blood pressure (141 +/- 3 vs 135 +/- 4 mm Hg, P =." | 1.31 | Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. ( Brown, M; Csako, G; Fleischer, TA; Koh, KK; Mincemoyer, R; Prasad, A; Quyyumi, AA; Schenke, WH; Selvaggi, TA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 13 (72.22) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akbari, H | 2 |
| Asadikaram, G | 3 |
| Jafari, A | 1 |
| Nazari-Robati, M | 1 |
| Ebrahimi, G | 1 |
| Ebrahimi, N | 2 |
| Masoumi, M | 3 |
| Vakili, S | 1 |
| Lüscher, TF | 1 |
| Sepehri, Z | 1 |
| Kiani, Z | 1 |
| Nasiri, AA | 1 |
| Kohan, F | 1 |
| Sheikh Fathollahi, M | 1 |
| Kazemi Arababadi, M | 1 |
| Sönmez, HM | 1 |
| Turan, FC | 1 |
| Köseoğlu, K | 1 |
| Deanfield, JE | 1 |
| Mancini, GB | 1 |
| Richter, MH | 1 |
| Richter, HR | 1 |
| Olbrich, HG | 1 |
| Mohr, FW | 1 |
| Trevelyan, J | 1 |
| Needham, EW | 1 |
| Morris, A | 1 |
| Mattu, RK | 1 |
| Sadamatsu, K | 1 |
| Shimokawa, H | 1 |
| Tashiro, H | 1 |
| Seto, T | 1 |
| Kakizoe, H | 1 |
| Yamamoto, K | 1 |
| Luchtefeld, M | 1 |
| Bandlow, N | 1 |
| Tietge, UJ | 1 |
| Grote, K | 1 |
| Pfeilschifter, J | 1 |
| Kaszkin, M | 1 |
| Beck, S | 1 |
| Drexler, H | 1 |
| Schieffer, B | 1 |
| Iwata, A | 1 |
| Miura, S | 1 |
| Imaizumi, S | 1 |
| Kiya, Y | 1 |
| Nishikawa, H | 1 |
| Zhang, B | 1 |
| Shimomura, H | 1 |
| Kumagai, K | 1 |
| Matsuo, K | 1 |
| Shirai, K | 1 |
| Saku, K | 1 |
| Apostolakis, S | 1 |
| Krambovitis, E | 1 |
| Vlata, Z | 1 |
| Kochiadakis, GE | 1 |
| Baritaki, S | 1 |
| Spandidos, DA | 1 |
| Longobardi, G | 1 |
| Corbi, G | 1 |
| Cacciatore, F | 1 |
| Abete, P | 1 |
| Furgi, G | 1 |
| Vitale, DF | 1 |
| Rengo, F | 1 |
| Ferrara, N | 1 |
| Morawietz, H | 1 |
| Rueckschloss, U | 1 |
| Niemann, B | 1 |
| Duerrschmidt, N | 1 |
| Galle, J | 1 |
| Hakim, K | 1 |
| Zerkowski, HR | 1 |
| Sawamura, T | 1 |
| Holtz, J | 1 |
| Prasad, A | 2 |
| Koh, KK | 1 |
| Schenke, WH | 1 |
| Mincemoyer, R | 1 |
| Csako, G | 1 |
| Fleischer, TA | 1 |
| Brown, M | 1 |
| Selvaggi, TA | 1 |
| Quyyumi, AA | 2 |
| Halcox, JP | 1 |
| Waclawiw, MA | 1 |
| Dell'Italia, LJ | 1 |
| Rocic, P | 1 |
| Lucchesi, PA | 1 |
1 review available for losartan and Coronary Artery Disease
| Article | Year |
|---|---|
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary A | 2002 |
6 trials available for losartan and Coronary Artery Disease
| Article | Year |
|---|---|
[The effect of losartan on the intima-media thickness of carotid artery].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Carot | 2008 |
Comparison of the effect of enalapril and losartan in conjunction with surgical coronary revascularisation versus revascularisation alone on systemic endothelial function.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Coronary Artery D | 2005 |
Different effects of simvastatin and losartan on cytokine levels in coronary artery disease.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reac | 2006 |
Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Biphenyl Compounds; Cells, Cultured; Corona | 2007 |
Do valsartan and losartan have the same effects in the treatment of coronary artery disease?
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Case-Control Studies; Coronary Angiography; Coronary | 2007 |
Effect of losartan in treatment of exercise-induced myocardial ischemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Coronary Artery Disease; Cross-Over Studies | 2007 |
11 other studies available for losartan and Coronary Artery Disease
| Article | Year |
|---|---|
Atorvastatin, losartan and captopril may upregulate IL-22 in hypertension and coronary artery disease; the role of gene polymorphism.
Topics: Adult; Aged; Atorvastatin; Captopril; Case-Control Studies; Coronary Artery Disease; Female; Genotyp | 2018 |
Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism.
Topics: Atorvastatin; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genotype; Humans; | 2019 |
Atherosclerosis, neoatherosclerosis, and vascular disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Aortic Diseases; Aortic Valve Stenosis; Cardiovascular Dise | 2015 |
Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension.
Topics: Antihypertensive Agents; Atorvastatin; Captopril; Coronary Artery Disease; Humans; Hydroxymethylglut | 2016 |
Targeting the atherosclerotic process in clinical practice. A new look at established agents.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Chan | 2002 |
Two good reasons for an angiotensin-II type 1 receptor blockade with losartan after cardiac transplantation: reduction of incidence and severity of transplant vasculopathy.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Coronary Artery D | 2003 |
CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2007 |
Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive A | 1999 |
Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; C-Reactive Protein; Cell Adhesion Molecul | 2001 |
Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Coronary Artery Disease; Coronary Vessels | 2001 |
Use of angiotensin-converting enzyme inhibitors in patients with diabetes and coronary artery disease.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bradykinin; Chyma | 2002 |